Show simple item record

dc.contributor.authorSivapalan, Pradeesh; email: Pradeesh.sivapalan.02@regionh.dk
dc.contributor.authorBikov, Andras; orcid: 0000-0002-8983-740X; email: andras.bikov@gmail.com
dc.contributor.authorSuppli Ulrik, Charlotte; email: csulrik@dadlnet.dk
dc.contributor.authorLapperre, Therese Sophie; orcid: 0000-0002-5176-0101; email: therese.lapperre@uza.be
dc.contributor.authorMathioudakis, Alexander G.; orcid: 0000-0002-4675-9616; email: alexander.mathioudakis@manchester.ac.uk
dc.contributor.authorHøjberg Lassen, Mats Christian; email: mats.christian.hoejbjerg.lassen@regionh.dk
dc.contributor.authorGrundtvig Skaarup, Kristoffer; email: kristoffer.grundtvig.skaarup@regionh.dk
dc.contributor.authorBiering-Sørensen, Tor; email: Tor.Biering-Soerensen@regionh.dk
dc.contributor.authorVestbo, Jørgen; email: jorgen.vestbo@manchester.ac.uk
dc.contributor.authorJensen, Jens-Ulrik S.; orcid: 0000-0003-4036-0521; email: jens.ulrik.jensen@regionh.dk
dc.date.accessioned2021-06-24T00:05:08Z
dc.date.available2021-06-24T00:05:08Z
dc.date.issued2021-06-21
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625026/additional-files.zip?sequence=2
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625026/jcm-10-02734.xml?sequence=3
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625026/jcm-10-02734.pdf?sequence=4
dc.identifier.citationJournal of Clinical Medicine, volume 10, issue 12, page e2734
dc.identifier.urihttp://hdl.handle.net/10034/625026
dc.descriptionFrom MDPI via Jisc Publications Router
dc.descriptionHistory: accepted 2021-06-16, pub-electronic 2021-06-21
dc.descriptionPublication status: Published
dc.descriptionFunder: Danish Regions Medical Fund; Grant(s): 5894/16
dc.descriptionFunder: Sundhed og Sygdom, Det Frie Forskningsråd; Grant(s): 6110-00268B
dc.description.abstractThe CORTICO-COP trial showed that eosinophil-guided corticosteroid-sparing treatment for acute exacerbation of chronic obstructive pulmonary disease was non-inferior to standard of care and decreased the accumulated dose of systemic corticosteroids that patients were exposed to by approximately 60%. Smoking status has been shown to affect corticosteroid responsiveness. This post hoc analysis investigated whether eosinophil-guided treatment is non-inferior to conventional treatment in current smokers. The main analysis of current smokers showed no significant difference in the primary endpoint, days alive, and out of hospital within 14 days between the control group (mean, 9.8 days; 95% confidence interval (CI), 8.7–10.8) and the eosinophil-guided group (mean, 8.7 days; 95% CI, 7.5–9.9; p = 0.34). Secondary analyses of the number of exacerbations or deaths, the number of intensive care unit admissions or deaths, lung function improvement, and change in health-related quality of life also showed no significant differences between the two groups. The results of a sensitivity analysis of ex-smokers are consistent with the main analysis. Our results suggest that eosinophil-guided treatment is non-inferior to standard of care in current smokers and ex-smokers. Because data on the impact of smoking status on eosinophil-guided treatments are sparse, more randomised trials are needed to confirm our results.
dc.languageen
dc.publisherMDPI
dc.rightsLicence for this article: https://creativecommons.org/licenses/by/4.0/
dc.sourceeissn: 2077-0383
dc.subjectchronic obstructive pulmonary disease
dc.subjectcorticosteroid resistance
dc.subjectsmoking
dc.subjectairway inflammation
dc.subjectblood eosinophils
dc.titleCorticosteroid Resistance in Smokers—A Substudy Analysis of the CORTICO-COP Randomised Controlled Trial
dc.typearticle
dc.date.updated2021-06-24T00:05:08Z
dc.date.accepted2021-06-16


Files in this item

Thumbnail
Name:
additional-files.zip
Size:
167.5Kb
Format:
Unknown
Thumbnail
Name:
jcm-10-02734.xml
Size:
13.10Kb
Format:
XML
Thumbnail
Name:
jcm-10-02734.pdf
Size:
1.121Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record